Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
Abstract Background Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believed to be related to immune dysregulations triggered by ICI can be serio...
Main Authors: | Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang, Mahvish Muzaffar, Mona A. Marie, Justin D. Mccallen, Shravanti Macherla, Darla Liles, Paul R. Walker |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0648-3 |
Similar Items
-
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
by: J. Boegeholz, et al.
Published: (2020-04-01) -
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
by: Anne Zaremba, et al.
Published: (2021-10-01) -
Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
by: Mona A. Marie, et al.
Published: (2022-12-01) -
Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
by: Melina Yerolatsite, et al.
Published: (2024-03-01) -
Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)